New oral diabetes contender
7:30–8:35 · 65s
Priya outlines a Lancet-funded trial showing Lilly’s oral GLP-1 (orforglipron) outperformed oral semaglutide for diabetes control, while noting side effects and ease-of-use tradeoffs.
7:30–8:35 · 65s
Priya outlines a Lancet-funded trial showing Lilly’s oral GLP-1 (orforglipron) outperformed oral semaglutide for diabetes control, while noting side effects and ease-of-use tradeoffs.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.